新辅助化疗与病理完全缓解对早期乳腺癌保乳手术资格的影响:荟萃分析
该荟萃分析纳入36项研究共12311例早期乳腺癌患者,评估新辅助系统治疗后病理完全缓解(pCR)与保乳手术(BCT)率的关系。平均BCT率为57%(95%CI 52-62%),平均pCR率为24%(95%CI 19-29%),但pCR与BCT率无显著关联(单因素p=0.34,校正后p=0.82)。结论认为pCR并未提高早期乳腺癌患者接受新辅助治疗后的保乳手术率。
要点
- 在新辅助治疗的早期乳腺癌患者中,pCR与保乳手术率无显著关联。
- 平均保乳手术率为57%,平均pCR率为24%,研究间异质性显著。
- 临床N分期和HER2状态与保乳手术率显著相关。
核心结论
- 对于接受新辅助系统治疗的早期乳腺癌患者,病理完全缓解并未增加保乳手术率。
研究设计与样本
- 随机试验的荟萃分析,共纳入36项研究、12311例早期乳腺癌患者。
- 主要终点为保乳手术率,次要终点为pCR率及其与BCT的关联。
- 采用随机效应模型,基于可评估患者以逆方差加权法进行荟萃分析。
主要发现
- 各治疗组保乳手术率范围为5%-76%,平均为57%(95%CI 52-62%)。
- 研究间异质性显著(Cochrane Q=787,p<0.001,I2=97%)。
- 各研究pCR率范围为3%-60%,所有研究组平均pCR率为24%(95%CI 19-29%)。
- pCR率与保乳手术率无显著关联(单因素p=0.34;校正HER2和临床淋巴结状态后p=0.82)。
- 在14项多组研究中,治疗组间pCR差异与BCT差异无显著关联(p=0.27)。
关键数值与推荐
- 临床N分期(p=0.01)和HER2状态(p=0.03)与保乳手术率显著相关。
- 保乳手术率与首次患者入组年份(p=0.89)、组织学分级(p=0.93)及激素受体状态(p=0.39)无显著关联。
临床怎么用
- 临床决策中不应仅依据pCR来预期或决定保乳手术的可行性。
- 临床N分期和HER2状态与保乳手术率相关,评估保乳资格时需综合考虑。
局限性
- 研究间异质性高(I2=97%),可能影响合并结果的解释。
- 仅16/36项研究同时报告了pCR和BCT数据,纳入分析的42个独立单元可能不全面。
- 荟萃分析为研究水平关联,非患者个体水平数据,无法排除混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We conducted a meta-analysis of randomised trials evaluating pathological complete response (pCR) and surgical outcomes after neoadjuvant systemic therapy (NST) in patients with early breast cancer (EBC). PATIENTS AND METHODS: The primary outcome was breast-conserving surgery (BCT) rate. Secondary outcomes were pCR rate and association to BCT. Meta-analyses were performed using random effects models that use inverse-variance weighting for each treatment arm based on evaluable patients. Point estimates are reported with 95% confidence interval (CI), and p < 0.05 was considered statistically significant. RESULTS: Thirty-six studies were identified (N = 12,311 patients). We selected for the analysis 16 of 36 studies reporting both pCR and BCT for at least one treatment arm. Arms per study ranged from one to six; 42 independent units were available to evaluate the association between pCR and BCT. BCT rate ranged 5-76% across arms with an average BCT of 57% (95% CI 52-62%). Significant heterogeneity was observed among the trials (Cochrane Q = 787, p < 0.001, I2 = 97%). In the meta-regression model, BCT rates were not significantly associated with year of first patient-in (p = 0.89), grade (p = 0.93) and hormone-receptor status (p = 0.39). Clinical N-stage (p = 0.01) and human epidermal growth factor receptor (HER2) status (p = 0.03) were significantly associated with BCT. pCR rate ranged 3-60% across studies. The average pCR across all study arms was 24% (95% CI 19-29%). No association was observed between pCR rate in a study arm and the resulting BCT rate in a univariate model (p = 0.34) nor after adjusting for HER2 and clinical nodal status (p = 0.82). In the subset of 14 multi-arm studies, no significant association was seen between the differences in pCR and BCT between treatment arms (p = 0.27). CONCLUSIONS: pCR does not increase BCT in patients receiving NST for EBC.
引用
- Criscitiello C, Golshan M, Barry WT, et al. Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis. Eur J Cancer. 2018. PMID: 29734046. doi:10.1016/j.ejca.2018.03.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。